Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223517 | 0.86 | NPC1 (0.63) | NPC1RAB9AMAPK1GAAGFER | |
| SCHEMBL6629286 | 0.84 | NPC1 (0.53) | NPC1RAB9AMAPK1GAAGFER | |
| SCHEMBL8465212 | 0.82 | GFER (0.56) | NPC1RAB9AMAPK1GFERAXL | |
| SCHEMBL7547176 | 0.82 | GFER (0.56) | NPC1RAB9AMAPK1GFERAXL | |
| SCHEMBL1729400 | 0.82 | GFER (0.61) | NPC1RAB9AMAPK1GFERAXL | |
| SCHEMBL7222770 | 0.82 | GFER (0.56) | NPC1RAB9AMAPK1GAAGFER | |
| SCHEMBL10271315 | 0.80 | RAB9A (0.66) | NPC1RAB9AMAPK1GAAMAPT | |
| SCHEMBL2756575 | 0.80 | RAB9A (0.67) | NPC1RAB9AMAPK1GAAMAPT | |
| SCHEMBL5968511 | 0.79 | GFER (0.57) | NPC1RAB9AMAPK1GFERAXL | |
| SCHEMBL13462723 | 0.79 | RAB9A (0.63) | NPC1RAB9AMAPK1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020238369-A1 | COMPOUND FOR INHIBITING RORγT ACTIVITY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 赛尔瑞成(北京)生命科学技术有限公司 | 2020-12-03 | — | — | WO | disclosed |
| US-9540323-B2 | 7-hydroxy-indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-17 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| CN-1320597-A | Antifungal agent, and preparation method and intermediate thereof | EISAI CO LTD (JP) | 2001-11-07 | — | — | CN | disclosed |
| CN-1061347-C | Antifungal agent and its preparation method and intermediate | EISAI CO LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
| CN-1045441-C | Antifungal agent, and preparation method and intermediate thereof | EISAI CO LTD (JP) | 1999-10-06 | — | — | CN | disclosed |
| CN-1219538-A | Antifungal agent, and preparation method and intermediate thereof | EISAI CO LTD (JP) | 1999-06-16 | — | — | CN | disclosed |
| US-5792781-A | EFFECTIVE AGAINST DERMATOMYCOSIS/VISCEROMYCOSIS CAUSED BY FUNGI, I.E., CANDIDA ALBICANS | EISAI CO., LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5789429-A | FUNGICIDE | EISAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| CN-1188765-A | Antifungal agent and its preparation method and intermediate | EISAI CO LTD (JP) | 1998-07-29 | — | — | CN | disclosed |
| US-5648372-A | TRIAZOLES | EISAI CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| CN-1113241-A | Antifungal agent, and preparation method and intermediate thereof | EISAI CO LTD (JP) | 1995-12-13 | — | — | CN | disclosed |
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885RAB9A 333/4885MAPK1 1647/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885RAB9A 333/4885MAPK1 1647/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885RAB9A 333/4885MAPK1 1647/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885RAB9A 333/4885MAPK1 1647/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885RAB9A 333/4885MAPK1 1647/4885 |
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY11, P2RY2 | NPC1 3115/4885RAB9A 2900/4885MAPK1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.